Ichilov Hospital in Tel Aviv reported success with its Covid drug


0


Ichilov Hospital in Tel Aviv has published the results of a study on the effect on Covid-19 of a drug called EXO-CD24, developed in the hospital. Thirty patients in moderate to severe condition received the drug, and 29 of them were discharged from hospital within three to five days. The 30th patient has not been reported. The results certainly give rise to hope for the future. However, it should be noted that several companies, in Israel and elsewhere, have reported good results from drugs to treat Covid-19, among them RedHill Biopharma Ltd. (TASE: RDHL), Kamada Ltd. (TASE: KMDA), Enlivex (TASE: ENLV) and Pluristem Therapeutics Inc. (Nasdaq: PSTI; TASE: PSTI: PSTI) and Bonus BioGroup (TASE: BONS). The current trial, like other trials conducted at this point, was without a control group, and no information was disclosed about how the patients were selected. All companies are carrying out more advanced trials, and so is the Ichilov Hospital. There is space in the market for more than one treatment, with each treatment operating a slightly different mechanism, but in order to reach the market, they will have to undergo more comprehensive and controlled double-blind trials. Many treatments for Covid-19 are in development around the world, but few have reached the market, among them the antiviral drug Remdesivir, a long-acting steroid treatment called Dexmethasone, and an antibody-based treatment. Among the Israeli companies, RedHill Biopharma has already undergone a small double-blind trial in which a trend towards efficacy was found for the product but the result was not clear, and the company has moved to phase II / III trials which, if successful, could lead to emergency approval. Pluristem is also in phase two control phase. Kamada conducted a trial similar in range to the one at Ichilov Hospital, and since her treatment is based on plasma from people who have recovered from the disease, a treatment method that has already been approved in principle in the United States, the Department of Health has already purchased it. Enlivex has also completed a trial similar to the one at Ichilov Hospital, and the FDA will be consulting on how to proceed. Bonus BioGroup recently started its first trial. Ichilov Hospital drug, developed by Professor Nader Arber, director of the hospital’s Integrated Cancer Prevention Center, relies on exosomes, tiny particles in cell fluid that play a role in cell-to-cell communication, where the researchers introduced CD24, a protein that removes excess immune cells, which are damaged by What it looks like when the immune system gets out of control. An overreactive immune system response is often worse for coronavirus patients than the effect of the virus itself, and most companies developing treatments for the severe stage of the disease are already trying to calm the immune system in various ways. Covid-related material brings Picodya rapid diagnosis from under the radar Enlivex reports strong treatment results in the second stage of Covid The preparation is given by inhaling it into the lungs once every twenty hours for a few minutes over a period of several days. The advantage of this method of administering treatment is that various elements of the immune system can be restricted, but only topically in the lungs, where the immune system causes damage, without causing side effects in the rest of the body and without over-suppressing the desired immune responses in other organs. . The director of Ichilov Hospital, Professor Ronnie Gamzo, said: “Professor Nader Arber is a talented researcher and doctor. The research he has conducted in his laboratory is innovative and sophisticated and may save Coronavirus patients. I personally help him obtain permits from the Ministry of Health to continue his comprehensive and in-depth research. ”It is now understood throughout the world that besides vaccines, it is very important to develop appropriate treatments for the disease, and a great deal of research is devoted to this. I am proud that we are now in Ichilov, among the first in the world, we are active in this field of research and may bring the beginning of some good news from Israel in the midst of a terrible global pandemic. Posted by Globes, Israeli Business News – en.globes.co.il – on February 7, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021


Like it? Share with your friends!

0

What's Your Reaction?

hate hate
0
hate
confused confused
0
confused
fail fail
0
fail
fun fun
0
fun
geeky geeky
0
geeky
love love
0
love
lol lol
0
lol
omg omg
0
omg
win win
0
win
Mitchel

0 Comments

Your email address will not be published. Required fields are marked *